Physician profile
Tyler A Moss
NPI 1285955039
$7,530.27
in general payments reported to CMS, 2019-2025
36 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $896 · 2021: $1,683 · 2022: $1,067 · 2023: $1,365 · 2024: $1,074 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,717.66 |
| Education | $297.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,985.71 | 2019-2025 | |
| Janssen Biotech, INC. | $1,125.86 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Almirall LLC | $839.96 | 2019-2025 | Klisyri |
| Lilly USA, LLC | $663.75 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $534.24 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $329.36 | 2019-2024 | Ilumya |
| Genzyme Corporation | $270.40 | 2019-2025 | |
| Pfizer INC. | $190.25 | 2019-2023 | |
| Dermavant Sciences, INC. | $189.94 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $153.42 | 2019-2025 | |
| Ucb, INC. | $151.67 | 2019-2024 | Bimzelx |
| Mayne Pharma Commercial LLC | $113.44 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.96 | 2019-2025 | Jublia |
| Amgen INC. | $94.81 | 2019-2024 | Otezla |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $90.47 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $69.37 | 2024 | Adbry |
| Galderma Laboratories, L.P. | $58.56 | 2019-2025 | Nemluvio |
| Revance Therapeutics, INC. | $58.50 | 2024-2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $58.07 | 2023-2024 | Sotyktu |
| Incyte Corporation | $55.36 | 2022-2023 | Opzelura |
| Organon LLC | $40.30 | 2023-2025 | Hadlima, Vtama |
| Strata Skin Sciences, INC. | $29.24 | 2024-2025 | Xtrac |
| Sensus Healthcare, INC. | $23.76 | 2024 | |
| Lnhc, INC | $22.43 | 2025 | Zelsuvmi |
| Organogenesis INC. | $21.07 | 2025 | Puraply Wound Matrix |
| Dermira, INC. | $21.02 | 2020 | |
| Kyowa Kirin, INC. | $20.45 | 2021 | |
| Botanix Sb INC | $20.24 | 2025 | Sofdra |
| Biowound Solutions, INC. | $17.39 | 2025 | Bio-Connekt |
| Biocon Biologics INC | $16.79 | 2025 | Yesintek |
| Arbor Pharmaceuticals, INC. | $15.12 | 2021 | |
| Boston Scientific Corporation | $14.92 | 2021 | |
| Glaxosmithkline, LLC. | $13.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.44 | 2023 | Cyltezo |
| Allergan, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.